{Reference Type}: Case Reports
{Title}: Successful Treatment of Refractory Cutaneous Protothecosis With MAT2203, an Oral Lipid Nanocrystal Formulation of Amphotericin B.
{Author}: Pechacek J;Schmitt MM;Ferrè EMN;Webb T;Goldberg J;Pathan S;Banerjee C;Barber P;DiMaggio T;Quinn A;Matkovits T;Castelo-Soccio L;Nussenblatt V;Lionakis MS;
{Journal}: Open Forum Infect Dis
{Volume}: 11
{Issue}: 8
{Year}: 2024 Aug
{Factor}: 4.423
{DOI}: 10.1093/ofid/ofae428
{Abstract}: Prototheca wickerhamii is a rare cause of cutaneous and systemic infection that requires long treatment courses with potentially toxic medications. We describe a patient with cutaneous protothecosis refractory to triazole monotherapy who experienced clinical and radiographic improvement with the novel oral lipid nanocrystal formulation of amphotericin B without experiencing toxicity.